Browse studies, page 718

Page 718 of 1,298, newest first. Search them all at once, ranked by relevance, in Evidence Hub.

• A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy ClinicalTrials.gov · COMPLETED, 2015
• A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Participants With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin ClinicalTrials.gov · COMPLETED, 2019
• A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) During 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control on MDI Insulin Regimen Alone or With Metformin ClinicalTrials.gov · COMPLETED, 2013
• Relative Bioavailability of Empagliflozin/Metformin Fixed-dose Combination - Empagliflozin 12.5 mg + Metformin 850mg (Boehringer Ingelheim) Coated Tablet Versus Jardiance® 10mg (Reference 1: Boehringer Ingelheim) Coated Tablet and Glifage® 850mg (Reference 2: Merck S / A. ) Coated Tablet, Administered Together in Healthy Male and Female Subjects Under Fed Conditions: an Open-label, Randomised, Single-dose, Two-way Crossover Study ClinicalTrials.gov · COMPLETED, 2021
• Bioequivalence of a Low Strength Fixed Dose Combination Tablet of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin, and Metformin Extended Release Tablets Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study) ClinicalTrials.gov · COMPLETED, 2018
• Is the Stepping-down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy? ClinicalTrials.gov · COMPLETED, 2018
• An Open Label, Randomized, Two-period, Two Treatment, Two-sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study to Compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR (Empagliflozin, Linagliptin, and Metformin Hydrochloride Extended-release Tablets) 25 mg/5 mg/1000 mg in Fed Condition ClinicalTrials.gov · COMPLETED, 2026
• Comparative Study of DPP-4 Inhibitors and SGLT-2 Inhibitors in Egyptian Diabetic Patients ClinicalTrials.gov · COMPLETED, 2022
• Bioequivalence of Empagliflozin/Metformin (500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study) ClinicalTrials.gov · COMPLETED, 2013
• Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 500 mg Tablets in Healthy Subjects Under Fed Conditions ClinicalTrials.gov · COMPLETED, 2025
• A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea ClinicalTrials.gov · COMPLETED
• Comparison of Empagliflozin- Linagliptin With Empagliflozin- Metformin Combination Therapy in Reduction of Body Weight in Type 2 Diabetes Mellitus ClinicalTrials.gov · COMPLETED, 2023
• Comparing the Effects of Empagliflozin and Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity ClinicalTrials.gov · COMPLETED, 2024
• A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus ClinicalTrials.gov · COMPLETED, 2014
• An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study of Test Product of Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet and Reference Product of Synjardy XR Tablets 25mg/1000mg in Healthy, Adult, Human Subjects Under Fed Condition ClinicalTrials.gov · COMPLETED, 2025
• An Open-label, Randomised, Single-dose, Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Two Fixed Dose Combination Tablets of Empagliflozin 12.5 mg and Metformin 500 mg Compared With the Free Combination of Empagliflozin 25 mg and Metformin 1000 mg Tablets Under Fed Conditions ClinicalTrials.gov · COMPLETED, 2015
• Comparison of Mean Blood Pressure in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin Versus Non-SGLT2 Oral Hypoglycemic Agents: A Randomized Controlled Trial ClinicalTrials.gov · COMPLETED, 2025
• A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control ClinicalTrials.gov · COMPLETED, 2013
• A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin and Empagliflozin 25 mg ClinicalTrials.gov · COMPLETED, 2024
• A Randomized, Comparator-controlled, Cross-over Intervention Study to Assess Renal Hemodynamics of Mono- and Combination Therapy With SGLT-2 Inhibitor Empagliflozin and RAS-inhibitor Losartan in Patients With Type 2 Diabetes Mellitus ClinicalTrials.gov · COMPLETED, 2021
• A Comparative Study of the Effect of Dapagliflozin Versus Empagliflozin ,Added to Metformin, on NAFLD in Patients With Type 2 Diabetes ClinicalTrials.gov · COMPLETED, 2024
• A Randomized, Open-label, Single Oral Dosing, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D745, and D150 for Healthy Subjects in Fed State ClinicalTrials.gov · COMPLETED, 2024
• Bioequivalence of Empagliflozin/Metformin (12.5mg/500mg) Fixed Dose Combination Tablets Compared to Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open Label, Randomised, Single Dose, Two Period, Two Sequence Crossover Study) ClinicalTrials.gov · COMPLETED, 2014
• A Randomized, Double-blind, Parallel-group, 2-treatment Multiple Dose Study to Assess the Intestinal, Metabolic and Cardiovascular Effects of an 8 Weeks Treatment With Sotagliflozin QD as Compared With Empagliflozin Once a Day (QD) in Type 2 Diabetes Mellitus (T2DM) Patients With Mild to Moderate Hypertension ClinicalTrials.gov · COMPLETED, 2019
• A Long-term, Randomized Study to Evaluate the Effects of Empagliflozin in Combination With Standard Hypoglycemic Therapy on Early and Long-term Results of Planned Percutaneous Coronary Interventions in Patients With Type 2 Diabetes ClinicalTrials.gov · COMPLETED, 2019
• Bioequivalence of Empagliflozin/Metformin (850 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study) ClinicalTrials.gov · COMPLETED, 2012
• The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity ClinicalTrials.gov · COMPLETED, 2026
• An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study of Test Product and Reference Product of Synjardy XR Tablets 25mg/1000mg in Healthy, Adult, Human Subjects Under Fasting Condition ClinicalTrials.gov · COMPLETED, 2026
• A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks With a 104 Week Extension Period in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Metformin Treatment ClinicalTrials.gov · COMPLETED, 2015
• Effects of Liraglutide, Empagliflozin and Linagliptin on Mild Cognitive Impairment Remission in Type 2 Diabetes (LIGHT-MCI): A Multicentre, Randomised Controlled Trial With An Extension Phase ClinicalTrials.gov · COMPLETED, 2026
• First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis Current problems in cardiology, 2021
• NEW validated stability-indicating RP-hplc method for the simultaneous determination of metformin hydrochloride, linagliptin and empagliflozin in bulk and pharmaceutical dosage forms International Journal of Applied Pharmaceutics, 2022
• Green spectrophotometric methods for simultaneous quantification of metformin, empagliflozin, and melamine Discover Chemistry, 2026
• The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark Diabetes Therapy, 2022
• Blunting p38 MAPKα and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation in mice intoxicated with carbon tetrachloride Life Science, 2021
• Analytical quality by design based on design space in reversed-phase-high performance liquid chromatography analysis for simultaneous estimation of metformin, linagliptin and empagliflozin Royal Society Open Science, 2022
• Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study BMC Endocrine Disorders, 2022
• Empagliflozin alone and in combination with metformin ameliorate diabetes type 2-oxidative stress Kufa Journal For Veterinary Medical Sciences, 2023
• A stability indicating assay method development and validation for the estimation of empagliflozin and metformin hydrochloride International journal of pharmaceutics and drug analysis, 2023
• The efficacy of combitation of empagliflozin and metformin in patients with arterial hypertension and type 2 diabetes mellitus Journal of Hypertension, 2023
• A review on method development and validation of stability indicating RP HPLC Method for metformin and Empagliflozin GSC Biological and Pharmaceutical Sciences, 2023
• A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation Cureus, 2023
• Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects Translational and Clinical Pharmacology, 2023
• Review on Method Development and Validation of Metformin, Empagliflozin and Glimepiride Using UPLC International Journal of Innovative Science and Research Technology, 2024
• Comparative Studies on Simultaneous Estimation of Metformin, Empagliflozin, Remogliflozin, Glimepride and Gliclazide by using RP-HPLC and Diol Technique International Journal of Drug Delivery Technology, 2024
• Effects of the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Empagliflozin Added to Metformin in Patients with Type 2 Diabetes Saudi Journal of Medical and Pharmaceutical Sciences, 2024
• Effectiveness of a fixed combination of empagliflozin with metformin in reduction of cardiovascular risk in patients with uncontrolled arterial hypertension and decompensated type 2 diabetes mellitus Ukrainian Therapeutical Journal, 2024
• 917-P: Sotagliflozin vs. Empagliflozin or Placebo in Type 2 Diabetes on a DPP-4i +/- Metformin Diabetes, 2024
• The influence of metformin and empagliflozin administration on gut microbiota in individuals with type 2 diabetes mellitus and hypothyroidism International Journal of Endocrinology, 2024
• Formulation and Evaluation of Extended-Release Bilayer Tablets Containing Empagliflozin and Metformin Hydrochloride for Diabetes Mellitus Management International Journal of Pharmaceutical Sciences and Drug Research, 2024
• Quantitative determination of potential genotoxic impurities in metformin hydrochloride and empagliflozin tablets through ultra-performance liquid chromatographymass spectrometry Journal of Pharmaceutical and Biomedical Analysis, 2024
• Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients Diabetes & Metabolism Journal, 2024
• Comparison of Efficacy of Empagliflozin Versus Dapagliflozin in Type 2 Diabetes Among Inadequately Controlled on Metformin/Glemipride/DPP4 at a Tertiary Care Hospital Biological and Clinical Sciences Research Journal, 2025
• Review on Simultaneous Estimation of Metformin Hydrochloride, Empagliflozin, Linagliptin Journal of Pharmaceutical Research International, 2025
• Comparative Study of Efficacy and Adverse Effects of Metformin Plus Empagliflozin Versus Metformin Plus Sitagliptin in Diabetes Mellitus Type II Patients Indus Journal of Bioscience Research, 2025
• Comparison of Empagliflozin Versus Vildagliptin in Combination with Metformin in Individuals Diagnosed with Type II Diabetes Mellitus Indus Journal of Bioscience Research, 2025
• An analytical of an experimental method for evaluation and validation from measuring dissolution of Metformin and Empagliflozin for generic tablets: Confirmation the results by docking method Revista Colombiana de Ciencias Químico Farmacéuticas, 2025
• A Validated Ion‐Pair Reversed‐Phase High‐Performance Liquid Chromatography for Simultaneous Quantification of Metformin Hydrochloride, Empagliflozin, and Linagliptin in the Antidiabetic Drug Combination and Dissolution Media Separation Science Plus, 2025
• Bioanalytical Method Development and Validation for The Estimation of Metformin and Empagliflozin in Blood Plasma by using RP-HPLC Research Journal of Pharmacy and Technology, 2025
• Development of a Sustainable High-Performance Liquid Chromatography (HPLC) Method for Quantifying Metformin, Sitagliptin, and Empagliflozin in Type 2 Diabetes Treatment Medical Forum Monthly, 2025
• To compare the efficacy and safety profile of empagliflozin and sitagliptin as an add on therapy to metformin in T2DM patients The Professional Medical Journal, 2025
• Comparative Analysis of Metformin and Empagliflozin in Male Wistar Rats with Non-Diabetic Chronic Kidney Disease Journal of Saidu Medical College, Swat, 2025
• Comparison of the effects of metformin and empagliflozin on cardiac function in heart failure with preserved ejection fraction mice Frontiers in Cardiovascular Medicine, 2025
• Role of Combination Therapy with SGLT2 Inhibitor with Metformin as Initial Treatment for Type2 Diabetes-Advantages of Oral Fixed Drug Pill Like Empagliflozin/Metformin in Patients with Cardiovascular and Renal Risk-A Short Communication Archives of Diabetes and Endocrine System, 2019
• Effect of Empagliflozin Metformin with Clomiphene Citrate versus Metformin with Clomiphene Citrate on cases of Polycystic Ovary Syndrome Journal of Medical and Scientific Research, 2023
• A Bioequivalence Study of Empagliflozin/Metformin Fixed-Dose Combination in Healthy Subjects under Fasting Conditions The Journal of Bioscience and Medicine, 2024
• Empagliflozin-Metformin in Hypertension Therapy Synergistically Upregulate 3-Hydroxy-3-Methylglutaryl-Coenzyme A Synthase 2 and Acetyl-coenzyme A acyltransferase 1B Physiology, 2025
• A Repurposed Duo: Empagliflozin-Metformin Triggers a Metabolic Crisis in Cervical Cancer by Disrupting the Acyl-CoA/CoA Ratio via Dual Inhibition of PPAT and CPT1A Journal of Cancer Research Updates, 2025
• Comparison of Empagliflozin-Linagliptin with Empagliflozin- Metformin Combination Therapy in Assessing Cardiovascular Profile and Anemia in Type 2 Diabetic Patients Journal of Bahria University Medical & Dental College, 2025
• Pharmacokinetic Comparison and Bioequivalence Evaluation of Two Empagliflozin/Metformin Fixed-Dose Combination Tablets in Healthy Subjects under Fed Conditions Open Journal of Endocrine and Metabolic Diseases, 2025
• Antidiabetes agents and risk of incident depression in 686,522 people with type 2 diabetes mellitus: A 20-year population-based cohort study Psychological medicine, 2026
• Green evaluation of human plasma levels of metformin, linagliptin, and empagliflozin using HPLC and HPTLC methods: a pharmacokinetic study BMC chemistry, 2026
• Enantioselective analysis of metoprolol in plasma of hypertensive patients undergoing long-term therapy: Insights for personalized medicine BioImpacts : BI, 2025
• Diagnostic and Management Pitfalls of SGLT2 Inhibitor-Associated Ketoacidosis in the ICU: Lessons Following Cardiac Surgery and GLP-1 Agonist Interaction Case reports in critical care, 2026
• Model-Informed Approaches for Pediatric Type 2 Diabetes Evidence Generation: Insights from a Model-Based Longitudinal HbA1c Meta-Analysis from EMA Marketing Authorization Applications Clinical pharmacology and therapeutics, 2026
• Empagliflozin / Metformin -- Benefit Assessment According to §35a Social Code Book V 2016
• GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1-40 in diabetes American journal of physiology. Heart and circulatory physiology, 2026
• Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants Obesity pillars, 2026
• Computational discovery of fenugreek-paitan-turmeric (FPT) bioactive compounds targeting SGLT2 and DPP-4 for glucose homeostasis regulation Journal of Taibah University Medical Sciences, 2026
• Prioritizing Antidiabetic Drugs for Inflammatory Bowel Disease Through Inverse Signal Detection: A FAERS Pharmacovigilance Study Journal of clinical medicine, 2026
• Balancing performance and sustainability: a white differential pulse voltammetry method for metformin and empagliflozin in plasma Bioanalysis, 2026
• Targeting metabolism to protect fertility and healthy pregnancy with SGLT2 inhibitors and GLP-1RAs Current opinion in physiology, 2026
• Antihyperglycemic treatment of type 2 diabetes mellitus (Update 2026) Wiener klinische Wochenschrift, 2026
• Dapagliflozin Beyond Glucose Lowering: Mechanisms of Renal and Systemic Protection Pathophysiology : the official journal of the International Society for Pathophysiology, 2026
• Drug-Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database Diabetes, obesity & metabolism, 2026
• Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database Frontiers in endocrinology, 2026
• Cardioprotective effects of metformin and empagliflozin in STZ-induced diabetic rats: Role of BACH1-mediated ferroptosis and YAP1/PD-L1 signaling Life sciences, 2026
• The Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026
• Effectiveness and Safety of Fixed-Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real-World Study From China Journal of diabetes, 2026
• Longitudinal Changes in Corneal Epithelial and Central Corneal Thickness in Type 2 Diabetes Assessed by AS-OCT: A Real-World Study Clinical ophthalmology (Auckland, N.Z.), 2026
• Silica-coated magnetic iron oxide functionalized with hydrophobic polymeric ionic liquid: a promising nanoscale sorbent for simultaneous extraction of antidiabetic drugs from human plasma prior to their quantitation by HPLC. RSC advances, 2018
• A Survey of the FDA's Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter-2 Inhibitor Use Diabetes therapy : research, treatment and education of diabetes and related disorders, 2019
• Antidiabetic Medicines Utilisation During Pre-Pandemic, Pandemic and Post-Pandemic Period of COVID-19-Data for Bulgarian Population Healthcare (Basel, Switzerland), 2025
• Role of oral hypoglycaemic drugs in preventing complication in non-alcoholic fatty liver disease with type 2 diabetes mellitus JPMA. The Journal of the Pakistan Medical Association, 2024
• Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China Journal of comparative effectiveness research, 2021
• Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study Biomedicines, 2023
• Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes Journal of diabetes research, 2022
• Pharmacokinetics of fixed-dose combinations of empagliflozin/metformin compared with individual tablets in healthy subjects International journal of clinical pharmacology and therapeutics, 2016
• Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes Expert opinion on pharmacotherapy, 2016
• Impact of empagliflozin as add-on to metformin vs metformin continuation on MASLD progression in type 2 diabetes: The IMAGIN Study Nutrition, metabolism, and cardiovascular diseases : NMCD, 2026